Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Distinct Migratory Dendritic Cells Cooperate to Prime Resident T Cells in Tumors

3 hours ago 9

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Tissue-resident memory CD8+ T cells inside solid tumors correlate with favorable patient prognosis and improved responsiveness to immune checkpoint blockade, yet the anatomical origins and cellular signals driving their specification remain poorly understood. In a study published in Nature Communications, an international research team investigated tumor-infiltrating lymphocytes in the KP mouse model of lung adenocarcinoma, driven by KrasG12D activation and p53 deletion. The authors discovered that the commitment of tumor-specific CD8+ T cells to a tissue-resident memory-like phenotype does not occur randomly inside established lesions, nor does it rely on a single antigen-presenting cell type. Instead, the generation of these protective resident lymphocytes requires an unexpected division of labor and cooperation between two distinct migratory classical dendritic cell lineages—XCR1-expressing type 1 dendritic cells and IRF4-dependent CD11b-expressing type 2 dendritic cells—operating within tumor-draining lymph nodes.

To characterize resident memory populations within pulmonary malignancies, the investigators mapped the immune landscape of grafted and autochthonous KP lung tumors using multiparameter flow cytometry, single-cell RNA sequencing, and CITE-Seq. Within the lung parenchyma, approximately 27.3 percent of CD8+ tumor-infiltrating lymphocytes expressed CD69 and CD103, representing the canonical tissue-resident memory phenotype. Concurrently, 21.7 percent of infiltrating CD8+ T cells displayed exhaustion markers, staining positive for PD-1 and TIM-3. Flow cytometry and single-cell transcriptomic clustering demonstrated substantial phenotypic overlap between resident and exhausted cells, resolving five activated CD44-positive, CD62L-negative clusters. Cluster 1 was distinguished by core residency transcripts, including Itgae, Cd69, Itga1, and Cxcr6, alongside the transcription factor Hobit. Intravenous injection of fluorescent anti-CD45.2 antibodies five minutes before euthanasia left CD69+CD103+ cells unstained, confirming their localization within the lung parenchyma rather than the surrounding vasculature.

Functional profiling demonstrated that despite expressing markers shared with exhausted T cells, tissue-resident memory-like lymphocytes retain potent anti-tumor activity. Following ex vivo restimulation with the OVA257–264 peptide in mice bearing ovalbumin-expressing KP tumors (KP-OVA), TIM-3-positive resident memory-like cells synthesized substantial amounts of interferon-gamma and tumor necrosis factor, with 15.5 percent producing cytokines compared to 11.9 percent of conventional TIM-3-positive exhausted cells. When co-cultured directly with KP-OVA tumor cells, sorted resident memory-like lymphocytes mediated target cytolysis, released granzyme B, and secreted higher levels of interferon-gamma than exhausted counterparts. Furthermore, systemic combination therapy with anti-PD-1 and anti-CTLA-4 antibodies expanded TIM-3-negative resident memory-like lymphocytes in the lungs. Concurrently, acute exposure to anti-PD-1 monotherapy markedly elevated the proportion of polyfunctional interferon-gamma and tumor necrosis factor double-positive cells among TIM-3-expressing tumor-infiltrating lymphocytes, underscoring their responsiveness to immunotherapeutic reactivation.

The research team next addressed where these cells receive their residency-inducing programming. To evaluate whether resident cells differentiate locally within lung tissue or originate through migration from regional lymphatics, the authors administered fingolimod (FTY720) to block sphingosine-1-phosphate receptor 1 and prevent lymphocyte egress from lymphoid tissues. Administering FTY720 every two to three days starting from day 1 or day 7 post-engraftment completely abolished the accumulation of activated CD44-positive, CD62L-negative CD8+ T cells in the lungs by day 14, severely depleting CD103-positive resident memory-like tumor-infiltrating lymphocytes. This demonstrated that continuous egress from tumor-draining mediastinal lymph nodes is an absolute requirement for establishing resident memory-like cells in lung lesions. Parallel examination of mediastinal lymph nodes in tumor-bearing mice identified a major expansion of activated CD8+ T cells, of which 41.3 percent expressed CD103, mirroring the 15.0 percent observed among ovalbumin-specific activated T cells in KP-OVA models.

To confirm that CD103-expressing activated T cells in lymph nodes serve as direct precursors of tumor-infiltrating resident memory lymphocytes, the researchers employed lineage tracing using inducible CD103-creERT2-ROSALSL-tdTomato reporter mice. Following tamoxifen administration, tdTomato fluorescent labeling occurred in 45.6 percent of CD103-positive activated T cells within tumor-draining lymph nodes, whereas only 1.5 percent of CD103-negative activated cells acquired the reporter, demonstrating high labeling specificity. Total lymph node suspensions from donor mice were adoptively transferred intravenously into tumor-bearing wild-type recipients. Five days later, donor-derived tdTomato-positive T cells differentiated predominantly into CD69+CD103+ resident memory-like cells, constituting 67.0 percent of the transferred activated donor CD8+ population. In contrast, tdTomato-negative donor cells yielded only 7.0 percent resident memory-like progeny, instead generating circulating effector and exhausted phenotypes. Single-cell transcriptomic projection confirmed that lung resident cluster 1 aligned with 84.25 percent specificity onto an activated lymph node cluster expressing high levels of CD103 and CXCR6.

Because dendritic cells orchestrate naive T lymphocyte activation in secondary lymphoid organs, the investigators characterized antigen-presenting cell subsets in mediastinal lymph nodes following tumor engraftment. Flow cytometry revealed marked increases in resident and migratory classical dendritic cells, separated into XCR1-positive type 1 dendritic cells (DC1s) and CD11b-positive type 2 dendritic cells (DC2s). Fate-mapping in Zbtb46-cre reporter mice confirmed that 73.2 percent of migratory CD11b-positive cells belonged to the classical dendritic cell lineage. To assess their non-redundant contributions, the team examined genetically modified mouse models: XCR1-DTA mice lacking DC1s, and CD11c-IRF4 mice lacking migratory DC2s while retaining resident DC2s. In DC1-deficient mice bearing KP-OVA tumors, the activation and clonal expansion of tumor-specific CD8+ T cells in draining lymph nodes was broadly suppressed, wiping out both CD103-negative and CD103-positive activated subsets.

In contrast to the broad immune impairment in DC1-deficient animals, the loss of migratory DC2s in CD11c-IRF4 mice left overall CD8+ T cell activation largely intact, but produced a selective deficit in CD103-positive and CD103-positive CXCR6-positive activated precursors. To eliminate the potential for developmental artifacts from constitutive gene deletion, the authors corroborated these findings using Mgl2-DTR mice, which express the diphtheria toxin receptor under the CD301b/MGL2 promoter active in migratory DC2s. Targeted administration of diphtheria toxin at days 2, 5, and 7 post-inoculation selectively depleted migratory DC2s in draining lymph nodes. This targeted intervention caused an isolated decline in antigen-specific CD103-positive activated T cells, while leaving CD103-negative activated populations unaffected. These complementary models demonstrated that while DC1s are indispensable for initiating general CD8+ T cell proliferation, migratory DC2s perform an obligatory role required to induce the CD103-positive resident precursor fate during lymph node priming.

The downstream consequences of impaired lymph node priming directly shaped the immune composition within pulmonary tumors. In tumor-bearing XCR1-DTA mice, lung infiltration by all CD8+ T cell subsets was virtually abolished, confirming that classical DC1s are necessary to generate the broad pool of cytotoxic lymphocytes. Conversely, tumor-bearing CD11c-IRF4 mice displayed normal infiltration of conventional effector and exhausted CD8+ T cells, but suffered a selective deficiency in both TIM-3-positive and TIM-3-negative resident memory-like lymphocytes. Similarly, diphtheria toxin-mediated depletion of migratory DC2s in Mgl2-DTR mice selectively reduced ovalbumin-specific resident memory-like cells in the lung without altering other subsets. To confirm that this defect originated during lymph node priming rather than local lung signaling, the researchers transferred total lymph node cells from wild-type, XCR1-DTA, or CD11c-IRF4 donors into standardized wild-type hosts. Donors lacking migratory DC2s reconstituted recipient lungs with normal numbers of total CD8+ T cells but exhibited impaired generation of resident memory-like progeny.

To dissect the mechanisms underlying this cooperation, the investigators sorted migratory DC1 and DC2 populations from tumor-draining lymph nodes and performed ex vivo cross-presentation co-cultures with CellTrace Violet-labeled, ovalbumin-specific naive OT-1 CD8+ T cells. Tracking fluorescent tumor antigens revealed that migratory DC1s transported more tumor material and exhibited over twofold higher surface density of peptide-MHC class I complexes (319.8 mean fluorescence intensity for H-2Kb-OVA) than migratory DC2s (132.8 mean fluorescence intensity). In culture, migratory DC1s stimulated robust OT-1 proliferation, but the activated cells remained almost entirely CD103-negative. Conversely, migratory DC2s induced milder division, yet drove strong CD103 expression on proliferating T cells. Adding synthetic SIINFEKL peptide onto DC2 cultures increased proliferation but extinguished CD103 upregulation. Testing altered peptide ligands of decreasing affinity (SIINFEKL, Q4, T4, and G4) demonstrated that weaker T cell receptor agonist activity progressively favored CD103 expression, proving that low peptide-MHC-I density on DC2s delivers a calibrated mild signal preserving CD103 induction.

In addition to antigen density, the researchers identified cytokine signaling as an essential regulator of resident memory specification. Migratory DC1s expressed high levels of interleukin-12, with 78.3 percent positivity in IL-12-YFP reporter mice compared to 15.9 percent in migratory DC2s. In co-cultures, adding recombinant interleukin-12 blunted CD103 induction by migratory DC2s without diminishing proliferation, consistent with interleukin-12-driven T-bet expression competing with SMAD3 at the CD103 promoter. Migratory DC2s instead displayed elevated levels of latent transforming growth factor-beta (TGF-beta) complexed via latency-associated peptide (LAP), promoting TGF-beta-dependent CD103 induction. Paradoxically, while interleukin-12 suppressed CD103, in vivo antibody blockade of IL-12p40 severely reduced CXCR6 expression on activated lymph node T cells. In vitro titration experiments revealed that optimal generation of dual-positive CD103+CXCR6+ resident precursors required cooperative integration: transforming growth factor-beta protected CD103 against TCR-mediated suppression, while low-to-moderate interleukin-12 signaling provided the necessary stimulus driving CXCR6 expression.

Transcriptomic profiling of OT-1 cells cross-primed ex vivo confirmed that dendritic cell identity is the primary driver of T cell differentiation, accounting for 84 percent of variance along the first principal component in bulk RNA sequencing. T cells primed by migratory DC2s exhibited enrichment in core tissue-residency, stemness, and SMAD4 target gene signatures, while repressing MTORC1 signaling and MYC target genes. Although migratory DC2 deficiency did not accelerate primary tumor growth in the mouse models tested—a limitation the authors attributed to the dominant anti-tumor role of DC1-dependent effectors and the lack of tools to selectively deplete resident cells—these findings reshape fundamental immunology. By establishing that migratory DC1s drive proliferation and CXCR6 induction via interleukin-12, while migratory DC2s deliver mild TCR stimulation and TGF-beta presentation to safeguard CD103 commitment, the study challenges models of rigid dendritic cell division of labor. These insights suggest that cancer vaccines and immunotherapies aimed at generating durable tissue-resident memory must orchestrate the balanced engagement of multiple dendritic cell subsets.

Subject of Research: Cooperation of migratory dendritic cell subsets in priming tissue-resident memory-like CD8+ T cells in mouse lung cancer

Article Title: Distinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors

Article References: Vaudiau, N., Bourdely, P., Semitekolou, M., Ok, A., Gorline, L., Coulibaly, A. S. K., Rastello, M., Semervil, A., Savoldelli, R., Gerber-Ferder, Y., do Carmo, F. L. R., Vétillard, M., Rood, A., Bornères, J., Abbas, A., Guillin, M., Weber, J., Bouallegue, S., Pamboukas, K., … Guermonprez, P. (2026). Distinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors. Nature Communications, 17(1), Article 10953. https://doi.org/10.1038/s41467-026-77641-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77641-7

Keywords: dendritic cells, tissue-resident memory T cells, CD8+ T cells, lung adenocarcinoma, tumor-draining lymph nodes, cross-presentation, interleukin-12, transforming growth factor-beta, CD103, CXCR6, cancer immunotherapy, immune checkpoint blockade, IRF4, XCR1, T cell receptor signaling, single-cell RNA sequencing, tumor-infiltrating lymphocytes

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway